Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reimbursement Questions Add To Compounding Regulation Debate

Executive Summary

Public Citizen asks whether CMS policy could have helped prevent the drug contamination at New England Compounding Center as Senate committee wants more information on states’ regulatory practices.

You may also be interested in...

CMS Doubts Power Of Purse To Stem Public Health Crises With Compounded Drugs

Medicare agency disagrees with HHS Office of Inspector General recommendation that providers be required to identify the source of compounded drugs submitted for Part B payment.

FDA Compounder Inspections: States Taking Early Leave

State inspectors did not accompany FDA for the full duration of facility inspections and now the agency is turning over the findings to them.

HHS Inspector General Investigating Drug Savings For Medicare In FY 2014 Work Plan

OIG is examining how Medicare could benefit if it shared in the drug discounts available through the 340B program, the potential impact of changes to Part B ASP reporting and other Medicare and Medicaid drug-related topics during this and the coming fiscal year.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts